Friday, September 21, 2007

Sosei completes Phase II trial of AD 337 for the treatment of fibromyalgia

A group trial investigated the efficacy, safety and tolerability of AD 337 in female subjects. The trial enrolled 103 patients across 18 centers in the U.K. and Australia with the primary study endpoint being the difference in the Fibromyalgia Impact Questionnaire score between active and placebo after four weeks of treatment, Sosei said.


No comments: